drugset
drugset / Trial / NCT06905652

Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants

NCT06905652 ↗

Phase 1 Completed 26 enrolled University Hospital, Basel, Switzerland
RandomizedCrossoverTriple-blindBasic science

Summary

Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA has been investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.

Timeline

Start
2025-07-29
Primary completion
2026-05-12
Completion
2026-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject R-3,4-methylenedioxymethamphetamine Unknown 300 mg —
Subject S-3,4-methylenedioxymethamphetamine Unknown 100 mg —

Indications

No indication recorded.